EGENESIS, INC.
Profile
Company Names
EGENESIS, INC.
Addresses
101 CAMBRIDGEPARK DR., SUITE 200, CAMBRIDGE, MA 02140
300 TECHNOLOGY SQUARE, SUITE 301, CAMBRIDGE, MA 02139
C/O CAMBRIDGE BIOLABS, 1 KENDALL SQUARE, BUILDING 200, 2ND FLOOR, SUITE 2203, CAMBRIDGE, MA 02139
1071 BEACON STREET, UNIT 2, BROOKLINE, MA 02446
Phone Numbers
617-939-3643
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
2015
State Incorporated:
DELAWARE
Total Amount Raised:
$265,038,349.00
Number of Funding Rounds:
5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2024-02-13
$25,419,995.00
$28,719,296.00
$3,299,301.00
Debt
4
2021-02-26
$124,999,955.00
$124,999,955.00
$0.00
Equity
3
2019-11-01
$100,000,000.00
$100,000,000.00
$0.00
Equity
2
2017-03-13
$12,618,399.00
$38,189,826.00
$25,571,427.00
Equity
1
2016-08-08
$2,000,000.00
$3,000,000.00
$1,000,000.00
People
First Name
Middle Name
Last Name
Titles
Related Companies
ISAAC
CIECHANOVER
DIRECTOR
MICHAEL
CURTIS
EXECUTIVE OFFICER, DIRECTOR
JUERGEN
ECKHARDT
DIRECTOR
KENNETH
FAN
EXECUTIVE OFFICER
STEVEN
GILLIS
DIRECTOR
TRUBION PHARMACEUTICALS, INC
| PHASERX INC
| PULMATRIX INC
| THERACLONE SCIENCES, INC.
| MIRINA CORP
| SURFACE LOGIX INC
| ACYLIN THERAPEUTICS, INC.
| BLUEBIRD BIO, INC.
| VARIATION BIOTECHNOLOGIES (US), INC.
| GROOVE BIOPHARMA CORP
| ALLOZYNE INC
| PHASERX, INC.
| VIRAL LOGIC SYSTEMS TECHNOLOGY CORP
| FARADAY PHARMACEUTICALS, INC.
| PULMATRIX OPERATING COMPANY, INC.
| LYCERA CORP
| PULMATRIX, INC.
| NEXGENIA INC.
| CODIAK BIOSCIENCES, INC.
| VBI VACCINES INC/BC
| NOHLA THERAPEUTICS INC.
| HOMOLOGY MEDICINES, INC.
| IMMUSANT, INC.
| ONCORESPONSE INC
| EGENESIS, INC.
| ARCH VENTURE FUND X, L.P.
| ARCH VENTURE FUND X OVERAGE, L.P.
| ARCH VENTURE FUND XI, L.P.
| HC BIOSCIENCE, INC.
| ARCH VENTURE FUND XII, L.P.
| PHEAST THERAPEUTICS, INC.
| SONOTHERA, INC.
| PRONIRAS CORP
| ONCORESPONSE, INC
LUCIO
IANNONE
DIRECTOR
GEOFF
MACKAY
EXECUTIVE OFFICER
BOB
MORE
DIRECTOR
BORIS
NIKOLIC
DIRECTOR
PAUL
SEKHRI
EXECUTIVE OFFICER, DIRECTOR
BRAD
SMITH
DIRECTOR
SAPNA
SRIVASTAVA
EXECUTIVE OFFICER
JULIE
SUNDERLAND
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Debt
2024-02-13
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#

